Intra-Cellular Therapies, Inc. ITCI announced positive top-line results from its late-stage study evaluating lumateperone 42 mg for the treatment of major depressive disorder (MDD). The stock climbed ...
Source LinkIntra-Cellular Therapies, Inc. ITCI announced positive top-line results from its late-stage study evaluating lumateperone 42 mg for the treatment of major depressive disorder (MDD). The stock climbed ...
Source Link
Comments